Wow, this person has been consistently accurate with their...

First 1031 Last

Share
Profile

Follow
kira1256

160 Posts.

45

02/11/23

21:05

Post #: 70699433
Share

Originally posted by Mason14: ↑

Lot's of talking going on here.

I'm wondering if anyone has addressed the fact that there is limited preclinical evidence that has demonstrated a significant benefit from intravenous administration of CF33 either as a single agent or in combination with an anti-PDL1 in every murine model tested? In cases were there may have been benefit, the clinical trial either administered the OV/combination immediately after transfection into the murine model or did not have a single-agent PDL1 arm.

Intratumoral administration of anti-cancer agents for metastatic cancers is not and has never been an effective method of administration. In metastases, cancer has spread around the body and in most cases the cancer sites are not accessible by a needle (just look below). Notice in the most recent announcement that they only accepted patients that had cancers close to the skin, and it was those specific cancer locations they were examining. Need I say that cancers in early stages that are close to the skin are removed surgically, so who exactly is your target market?

Oncolytic viral therapy has always struggled to penetrate the tumor microenvironment, survive the immune system, and display significant efficacy in the clinic, which is why it's worth just $23-84M globally. Not to mention it is a crowded space with 114 clinical trials currently underway.

If CF33 as a single agent or in combination with any drug can't demonstrate a significant benefit administered intravenously, then it will fail in the clinic and commercialisation. I think IMU is about to head below 10c as people begin to understand the significant clinical and commercial risks associated with CF33, and with the realisation that HER-VAXX was a substandard therapy hyped as superior.

Expand

Wow, this person has been consistently accurate with their predictions.

IMU Price at posting: 4.3¢ Sentiment: Sell Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

There are more pages in this discussion • 57 more messages in this thread...

First 1031 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.3¢		Change -0.002(2.78%)		Mkt cap ! $389.5M

Open	High	Low	Value	Volume
5.5¢	5.6¢	5.3¢	$427.4K	7.935M

Buyers (Bids)

No.	Vol.	Price($)
24	1893654	5.2¢

Sellers (Offers)

Price($)	Vol.	No.
5.3¢	542899	16

View Market Depth

No.	Vol.	Price($)
23	1889435	0.052
19	1684682	0.051
40	3497778	0.050
36	5190185	0.049
20	1620835	0.048

Price($)	Vol.	No.
0.053	506899	14
0.054	1536486	12
0.055	1122953	7
0.056	1608503	12
0.057	1299298	8

Last trade - 14.30pm 11/07/2024 (20 minute delay)

IMU (ASX) Chart

Wow, this person has been consistently accurate with their...

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Wow, this person has been consistently accurate with their...

Top Stories

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News